NIH Clinical Trial Integrity Act

Bill Summary: NIH Clinical Trial Integrity Act (S 3564)

Overview

The NIH Clinical Trial Integrity Act is a legislative proposal designed to increase the diversity and inclusivity of clinical trials funded by the National Institutes of Health (NIH). The bill mandates that research organizations implement rigorous recruitment and retention goals to ensure that the participants in clinical trials accurately reflect the diverse demographics (race, ethnicity, age, and sex) of the populations affected by the diseases or conditions being studied.

Main Purpose and Intent

The primary goal of this bill is to ensure that biomedical and behavioral research produces results that are scientifically valid and applicable to all segments of the U.S. population. By mandating diversity in trial participants and reducing barriers to entry, the Act seeks to eliminate health disparities and ensure that new drugs, devices, and interventions are safe and effective for everyone, regardless of their demographic background.

Key Provisions

1. Enhanced Diversity Requirements for Funding

Any research organization seeking NIH funding or approval for a clinical trial must now submit an application that includes:
* Measurable Goals: Clear targets for recruiting and retaining participants based on race, ethnicity, age, and sex.
* Scientific Rationale: A detailed explanation of how participant numbers were determined and the specific strategies used to reach diverse populations.
* Analysis Plans: A requirement to analyze data from different population groups separately to determine specific safety and effectiveness outcomes.
* Participant Accessibility: A plan to reduce the burden on participants through "alternative follow-up requirements," such as telemedicine, wearable technology, home visits, or evening/weekend hours.

2. Accountability and Transparency

As a condition of funding, research organizations must agree to:
* Annual Reporting: Share aggregate demographic data and retention rates (disaggregated by race, ethnicity, age, and sex) with the Secretary of Health and Human Services (HHS).
* Mandatory Training: Ensure that clinical trial researchers complete education and training programs focused on diversity in clinical trials.
* Final Reporting: Submit final participant counts by demographic group upon the conclusion of the trial.

3. Removing Economic and Regulatory Barriers

The Act directs the Secretary of HHS to conduct a study within two years of enactment to modernize regulations regarding:
* Reimbursement for out-of-pocket expenses for human subjects.
* Compensation for time spent participating in trials.
* Updating "safe harbor" rules under the Federal Anti-Kickback Statute to ensure recruitment incentives are legal and accessible.

4. Public Awareness and Education

The bill establishes a national campaign to educate the public and healthcare professionals on the importance of diverse trials, including:
* Public Service Announcements (PSAs): Target campaigns to encourage underrepresented groups to participate.
* Professional Curricula: Training for healthcare providers on how to enroll diverse patients.
* Grant Program: Funding for nonprofit entities, faith communities, and community pharmacies to test new outreach strategies and cover administrative costs associated with diversifying trials.

Who is Affected?

• NIH-Funded Researchers: Must adhere to stricter application, reporting, and training requirements.
• Clinical Trial Participants: Will likely see reduced burdens for participation (e.g., more virtual options) and potential improvements in compensation.
• Underrepresented Populations: Will have increased outreach and better representation in medical research.
• Nonprofit/Community Organizations: Eligible for grants to assist in recruitment and education efforts.

Timeline and Budget

• Implementation: Recruitment requirements begin upon the date of enactment.
• Regulatory Study: Must be completed within 2 years of enactment.
• Funding: The bill authorizes $10,000,000 per fiscal year from 2026 through 2029 specifically for the public awareness and education campaign.